Published in Proc Natl Acad Sci U S A on March 15, 1993
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci U S A (1995) 1.89
Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. Mol Biol Cell (2001) 1.54
Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol (1995) 1.52
Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A (2006) 1.41
Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J Exp Med (1994) 1.25
Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. Proc Natl Acad Sci U S A (1997) 1.17
Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol Cell Biol (1996) 1.17
Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. EMBO J (1993) 1.14
Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface. Protein Sci (1996) 1.08
Evidence for a critical role for the cytoplasmic region of the interleukin 2 (IL-2) receptor gamma chain in IL-2, IL-4, and IL-7 signalling. Mol Cell Biol (1994) 1.07
An alpha-helical signal in the cytosolic domain of the interleukin 2 receptor beta chain mediates sorting towards degradation after endocytosis. J Cell Biol (1997) 1.05
Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. Proc Natl Acad Sci U S A (1994) 0.96
The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor beta chain, and induces lymphokine-activated killer cells. J Exp Med (2000) 0.81
Homology model of human interferon-alpha 8 and its receptor complex. Protein Sci (1995) 0.81
Solution assembly of the pseudo-high affinity and intermediate affinity interleukin-2 receptor complexes. Protein Sci (1999) 0.80
Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol (1995) 0.78
Characterisation and expression analysis of interleukin 2 (IL-2) and IL-21 homologues in the Japanese pufferfish, Fugu rubripes, following their discovery by synteny. Immunogenetics (2004) 0.78
Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. Br J Cancer (1994) 0.77
Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer. Mediators Inflamm (2016) 0.75
High resolution two-dimensional electrophoresis of proteins. J Biol Chem (1975) 133.45
Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A (1990) 7.39
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37
Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med (1984) 6.45
Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science (1989) 5.08
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature (1984) 4.95
Autoradiography using storage phosphor technology. Electrophoresis (1990) 4.61
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med (1987) 4.53
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science (1991) 3.84
A new cytokine receptor superfamily. Trends Biochem Sci (1990) 3.24
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol (1985) 3.18
A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature (1987) 3.00
Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell (1991) 2.84
Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A (1987) 2.65
A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell (1991) 2.49
The multi-subunit interleukin-2 receptor. Annu Rev Biochem (1989) 2.37
Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor. J Exp Med (1989) 2.15
The interleukin 2 receptor. Annu Rev Cell Biol (1989) 1.73
Three-dimensional structure of interleukin-2. Science (1987) 1.63
Structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity. J Biol Chem (1987) 1.43
Unraveling the structure of IL-2. Science (1992) 1.34
An associated molecule, p64, with IL-2 receptor beta chain. Its possible involvement in the formation of the functional intermediate-affinity IL-2 receptor complex. J Immunol (1992) 1.33
The human interleukin 2 receptor beta chain (p70). Direct identification, partial purification, and patterns of expression on peripheral blood mononuclear cells. J Exp Med (1988) 1.28
Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc Natl Acad Sci U S A (1988) 1.22
Response. Science (1992) 1.13
Structure-function relationships for the IL 2-receptor system. I. Localization of a receptor binding site on IL 2. J Immunol (1986) 1.11
Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction. EMBO J (1990) 1.11
An associated molecule, p64, with high-affinity interleukin 2 receptor. Int Immunol (1990) 1.10
IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody. Int Immunol (1989) 1.08
Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. Proc Natl Acad Sci U S A (1991) 1.06
Structure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysis. Proc Natl Acad Sci U S A (1988) 1.06
Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction. J Biol Chem (1987) 1.06
The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. Proc Natl Acad Sci U S A (1992) 1.04
The IL-2 receptor beta-chain (p70). Ligand binding ability of the cDNA-encoding membrane and secreted forms. J Immunol (1990) 1.02
Quantitative characterization of the intrinsic ligand-binding affinity of the interleukin 2 receptor beta chain and its modulation by the alpha chain and a second affinity-modulating element. Lymphokine Cytokine Res (1991) 0.97
Receptor binding and internalization of mouse interleukin-2 derivatives that are partial agonists. J Biol Chem (1992) 0.96
The IL-2 receptor alpha-chain alters the binding of IL-2 to the beta-chain. J Immunol (1991) 0.93
Regulation of the interleukin 2 receptor complex tyrosine kinase activity in vitro. Cytokine (1991) 0.90
Characterization of a tyrosine kinase activity associated with the high-affinity interleukin 2 receptor complex. Biochem J (1992) 0.83
The construction and characterization of a biologically active recombinant IL-2 containing a lysine-rich C-terminal extension. J Immunol (1988) 0.82
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med (1984) 6.45
Isolation of novel virus-like sequences associated with human hepatitis. Nat Med (1995) 4.99
Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. Proc Natl Acad Sci U S A (1983) 4.83
Differential function of major histocompatibility complex antigens in T-lymphocyte activation. Nature (1976) 3.87
Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A (1995) 3.30
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
Cell mediated immunity: separation of cells involved in recognitive and destructive phases. Science (1973) 3.04
Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. J Exp Med (1983) 2.82
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.76
Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A (1987) 2.65
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol (1983) 2.65
The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J Immunol (1984) 2.60
Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis. J Virol (1995) 2.38
Heterogeneity of human T-cell growth factor(s) due to variable glycosylation. Mol Immunol (1981) 2.34
Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans. Proc Natl Acad Sci U S A (1999) 2.22
Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses. J Infect Dis (1999) 2.21
Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. J Exp Med (1987) 2.15
Purification and partial sequence analysis of human T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.09
Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells. J Exp Med (1985) 1.99
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med (1983) 1.99
HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes. Science (1975) 1.91
Immunologic functions of isolated human lymphocyte subpopulations. III. Specific allogeneic lympholysis mediated by human T cells alone. J Immunol (1975) 1.83
Antigenic requirements for triggering of cytotoxic T lymphocytes. Immunol Rev (1977) 1.82
The heavy chain of human histocompatibility antigen HLA-B7 contains an immunoglobulin-like region. Nature (1979) 1.70
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Molecular and serologic analysis in the transmission of the GB hepatitis agents. J Med Virol (1995) 1.67
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2. J Immunol (1985) 1.62
Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol (1987) 1.60
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol (1984) 1.54
Sequence of the COOH-terminal hydrophilic region of histocompatibility antigens HLA-A2 and HLA-B7. J Biol Chem (1978) 1.52
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol (1985) 1.50
Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood (1994) 1.50
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med (1990) 1.50
Amplification and subtraction methods and their application to the discovery of novel human viruses. J Med Virol (1997) 1.44
Human T-cell growth factor: purification biochemical characterization, and interaction with a cellular receptor. Immunobiology (1982) 1.43
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J Immunol (1986) 1.40
Sequence heterogeneity within the 5'-terminal region of the hepatitis GB virus C genome and evidence for genotypes. J Hepatol (1996) 1.35
Posttranslational modification of human T-cell growth factor. Biochem Biophys Res Commun (1983) 1.35
Conversion of low-affinity interleukin 2 receptors to a high-affinity state following fusion of cell membranes. Proc Natl Acad Sci U S A (1986) 1.32
Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction. J Med Virol (1996) 1.31
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res (1989) 1.29
Retention of biological activity following radioiodination of human interleukin 2: comparison with biosynthetically labeled growth factor in receptor binding assays. J Immunol Methods (1985) 1.27
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res (1997) 1.27
Receptors for T-cell growth factor: structure, function and expression on normal and neoplastic cells. Contemp Top Mol Immunol (1985) 1.26
Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol (1987) 1.26
Phorbol diester induces expression of Tac antigen on human acute T lymphocytic leukemic cells. J Immunol (1984) 1.25
Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci U S A (1996) 1.23
Rapid purification of detergent-solubilized HLA antigen by affinity chromatography employing anti-beta2-microglobulin serum. J Biol Chem (1976) 1.23
Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro. J Immunol (1976) 1.22
The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol (1984) 1.22
Genetic control of mixed leukocyte culture reactivity. Transplant Rev (1972) 1.21
The human receptor for T-cell growth factor. Evidence for variable post-translational processing, phosphorylation, sulfation, and the ability of precursor forms of the receptor to bind T-cell growth factor. J Biol Chem (1985) 1.20
Human interleukin 2. Methods Enzymol (1985) 1.20
Identification of GB virus C variants by phylogenetic analysis of 5'-untranslated and coding region sequences. J Virol (1997) 1.19
Submit and disulfide structure of monomeric and dimeric forms of detergent-soluble HLA antigens. J Biol Chem (1977) 1.18
Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology (1996) 1.18
Amino acid sequence and post-translational modification of human interleukin 2. Proc Natl Acad Sci U S A (1984) 1.13
MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells. J Immunol (1992) 1.13
A multigene family on human chromosome 12 encodes natural killer-cell lectins. Immunogenetics (1993) 1.12
Recognitive specificity of human cytotoxic T lymphocytes. I. Antigen-specific inhibition of human cell-mediated lympholysis. J Exp Med (1975) 1.11
Rabbit anti-HL-A2 sera. Transplantation (1975) 1.11
Structure-function relationships for the IL 2-receptor system. I. Localization of a receptor binding site on IL 2. J Immunol (1986) 1.11
Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. J Immunol (1993) 1.11
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res (1996) 1.10
Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol (2001) 1.10
Isolation of a GB virus-related genome from a chimpanzee. J Med Virol (1998) 1.09
Identification of a membrane antigen that is distinct from the interleukin 2 receptor and that may be required for interleukin 2-driven proliferative responses. J Immunol (1983) 1.09
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Molecular cloning and characterization of a GB virus C isolate from a patient with non-A-E hepatitis. J Gen Virol (1996) 1.07
Secondary cell-mediated lympholysis: importance of H-2 LD and SD factors. J Exp Med (1976) 1.07
Proliferation of T lymphocytes in response to interleukin 2 varies with their state of activation. J Immunol (1986) 1.07
Interaction of IL-15 with the shared IL-2 receptor beta and gamma c subunits. The IL-15/beta/gamma c receptor-ligand complex is less stable than the IL-2/beta/gamma c receptor-ligand complex. J Immunol (1996) 1.06
Affinity-purified interleukin 2 induces proliferation of large but not small B cells. Proc Natl Acad Sci U S A (1985) 1.06
Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol (1986) 1.06
Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst (1988) 1.06
Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther (2000) 1.05
Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest (1987) 1.04
Complete amino acid sequence of a papain-solubilized human histocompatibility antigen HLA-B7. 1. Isolation and amino acid composition of fragments and of tryptic and chymotryptic peptides. Biochemistry (1979) 1.03
Human T-cell growth factor: purification and interaction with a cellular receptor. Lymphokine Res (1982) 1.02
Structure-function relationships for the IL 2-receptor system. II. Localization of an IL 2 binding site on high and low affinity receptors. J Immunol (1986) 1.02
WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis. Infect Immun (1992) 1.00
Soluble bacterial antigen induces specific helper and cytotoxic responses by human lymphocytes in vitro. J Immunol (1982) 1.00
Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci U S A (1999) 0.99
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol (1996) 0.99
Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins. Clin Diagn Lab Immunol (1999) 0.98